Skip to main content
Premium Trial:

Request an Annual Quote

Quest Exercises Option on Clinical Genomics Colon Cancer Markers

NEW YORK (GenomeWeb News) – Australian firm Clinical Genomics today said that Quest Diagnostics has exercised an option to use the firm's gene-based biomarkers in the development of new tests for colon cancer.

Clinical Genomics didn't specify the markers but said that they are two genes that are associated with colorectal cancer and can be detected through blood testing. It also said that Quest intends to incorporate markers into future generations of its ColoVantage laboratory-developed test, which is currently based on the Septin9 biomarker and is offered to physicians in the US.

Terms of the license were not disclosed.

"Quest’s research and development expertise and national scale position it well to maximize the clinical potential of our gene markers as a testing service to aid colon cancer detection in the United States," Clinical Genomics CEO Lawrence LaPointe said in a statement.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.